The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
New facility is part of Aptar Pharma’s global expansion program
PhytoSquene now available for clinical and commercial use
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Moist wound dressing for chronic wound treatment now available in Germany
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
Subscribe To Our Newsletter & Stay Updated
